BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tachezy M, Gebauer F, Janot M, Uhl W, Zerbi A, Montorsi M, Perinel J, Adham M, Dervenis C, Agalianos C, Malleo G, Maggino L, Stein A, Izbicki JR, Bockhorn M. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery. 2016;160:136-144. [PMID: 27048934 DOI: 10.1016/j.surg.2016.02.019] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Antoniou E, Margonis GA, Sasaki K, Andreatos N, Polychronidis G, Pawlik TM, Pikoulis E. Is resection of pancreatic adenocarcinoma with synchronous hepatic metastasis justified? A review of current literature: Pancreatic adenocarcinoma and liver metastases. ANZ Journal of Surgery 2016;86:973-7. [DOI: 10.1111/ans.13738] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
2 Breton C, Meyer A, Malka D, Matias M, De Baere T, Hammel P, Sa Cunha A, Lucchese A, Fuks D, Coriat R, Gallois C, Touchefeu Y, Maillet M, Trouilloud I, Rompteaux P, Carbonnel F, Soularue E. Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. Clin Res Hepatol Gastroenterol 2021;45:101607. [PMID: 33662776 DOI: 10.1016/j.clinre.2020.101607] [Reference Citation Analysis]
3 Klar E, Büchler MW, Lang H, Lordick F, Mittler J, Mizuno T, Torzilli G, Ulrich A, Vauthey JN. Oligometastases of Gastrointestinal Cancer Origin. Visc Med 2017;33:76-81. [PMID: 28612021 DOI: 10.1159/000463468] [Reference Citation Analysis]
4 Schwarz C, Kaczirek K, Bodingbauer M. Liver resection for non-colorectal metastases. Eur Surg 2018;50:113-6. [PMID: 29875799 DOI: 10.1007/s10353-018-0528-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hua YQ, Wang P, Zhu XY, Shen YH, Wang K, Shi WD, Lin JH, Meng ZQ, Chen Z, Chen H. Radiofrequency ablation for hepatic oligometastatic pancreatic cancer: An analysis of safety and efficacy. Pancreatology. 2017;17:967-973. [PMID: 29129384 DOI: 10.1016/j.pan.2017.08.072] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
6 Vorobyov N, Rykov I, Orlova R, Cherkashin M. Chemotherapy in combination with stereotactic body radiation therapy (SBRT) for oligometastatic pancreatic cancer. BMJ Case Rep 2018;2018:bcr-2018-225846. [PMID: 30219780 DOI: 10.1136/bcr-2018-225846] [Reference Citation Analysis]
7 Dhayat SA, Mirgorod P, Lenschow C, Senninger N, Anthoni C, Vowinkel T. Challenges in pancreatic adenocarcinoma surgery - National survey and current practice guidelines. PLoS One 2017;12:e0173374. [PMID: 28267771 DOI: 10.1371/journal.pone.0173374] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Furuse J, Shibahara J, Sugiyama M. Development of chemotherapy and significance of conversion surgery after chemotherapy in unresectable pancreatic cancer. J Hepatobiliary Pancreat Sci 2018;25:261-8. [DOI: 10.1002/jhbp.547] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
9 Hackert T, Niesen W, Hinz U, Tjaden C, Strobel O, Ulrich A, Michalski C, Büchler M. Radical surgery of oligometastatic pancreatic cancer. European Journal of Surgical Oncology (EJSO) 2017;43:358-63. [DOI: 10.1016/j.ejso.2016.10.023] [Cited by in Crossref: 85] [Cited by in F6Publishing: 77] [Article Influence: 17.0] [Reference Citation Analysis]
10 Tsutsumi C, Abe T, Shinkawa T, Nishihara K, Tamiya S, Nakano T. Long-term survival after hepatectomy for metachronous liver metastasis of pancreatic ductal adenocarcinoma: a case report. Surg Case Rep 2020;6:157. [PMID: 32621095 DOI: 10.1186/s40792-020-00924-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Sakaguchi T, Valente R, Tanaka K, Satoi S, Del Chiaro M. Surgical treatment of metastatic pancreatic ductal adenocarcinoma: A review of current literature. Pancreatology 2019;19:672-80. [PMID: 31285145 DOI: 10.1016/j.pan.2019.05.466] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
12 Crippa S, Cirocchi R, Weiss MJ, Partelli S, Reni M, Wolfgang CL, Hackert T, Falconi M. A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. Updates Surg 2020;72:39-45. [PMID: 31997233 DOI: 10.1007/s13304-020-00710-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
13 Matsuki R, Sugiyama M, Takei H, Kondo H, Fujiwara M, Shibahara J, Furuse J. Long-term survival with repeat resection for lung oligometastasis from pancreatic ductal adenocarcinoma: a case report. Surg Case Rep 2018;4:26. [PMID: 29589221 DOI: 10.1186/s40792-018-0435-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
14 Kandel P, Wallace MB, Stauffer J, Bolan C, Raimondo M, Woodward TA, Gomez V, Ritter AW, Asbun H, Mody K. Survival of Patients with Oligometastatic Pancreatic Ductal Adenocarcinoma Treated with Combined Modality Treatment Including Surgical Resection: A Pilot Study. J Pancreat Cancer 2018;4:88-94. [PMID: 30631861 DOI: 10.1089/pancan.2018.0011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
15 Kartalis N. CT and MRI of pancreatic cancer: there is no rose without a thorn! Eur Radiol 2018;28:3482-3. [DOI: 10.1007/s00330-018-5486-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
16 Shao Y, Feng J, Hu Z, Wu J, Zhang M, Shen Y, Zheng S. Feasibility of pancreaticoduodenectomy with synchronous liver metastasectomy for oligometastatic pancreatic ductal adenocarcinoma - A case-control study. Ann Med Surg (Lond) 2021;62:490-4. [PMID: 33680449 DOI: 10.1016/j.amsu.2020.11.037] [Reference Citation Analysis]
17 Traub B, Link KH, Kornmann M. Curing pancreatic cancer. Semin Cancer Biol 2021:S1044-579X(21)00160-7. [PMID: 34062264 DOI: 10.1016/j.semcancer.2021.05.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Fu N, Jiang Y, Weng Y, Chen H, Deng X, Shen B. Worth it or not? Primary tumor resection for stage IV pancreatic cancer patients: A SEER-based analysis of 15,836 cases. Cancer Med 2021;10:5948-63. [PMID: 34288562 DOI: 10.1002/cam4.4147] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Frigerio I, Regi P, Giardino A, Scopelliti F, Girelli R, Bassi C, Gobbo S, Martini PT, Capelli P, D'Onofrio M, Malleo G, Maggino L, Viviani E, Butturini G. Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery? Ann Surg Oncol 2017;24:2397-403. [PMID: 28516291 DOI: 10.1245/s10434-017-5885-4] [Cited by in F6Publishing: 35] [Reference Citation Analysis]
20 De Simoni O, Scarpa M, Tonello M, Pilati P, Tolin F, Spolverato Y, Gruppo M. Oligometastatic Pancreatic Cancer to the Liver in the Era of Neoadjuvant Chemotherapy: Which Role for Conversion Surgery? A Systematic Review and Meta-Analysis. Cancers (Basel) 2020;12:E3402. [PMID: 33213022 DOI: 10.3390/cancers12113402] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
21 Fonseca GM, Braghiroli MIFM, Pirola Kruger JA, Coelho FF, Herman P. Is There a Role for Locoregional Therapies for Non-colorectal Gastrointestinal Malignancies? Surg Oncol Clin N Am 2021;30:125-42. [PMID: 33220801 DOI: 10.1016/j.soc.2020.08.004] [Reference Citation Analysis]
22 Belyaev O, Bösch F, Brunner M, Müller-debus CF, Radulova-mauersberger O, Wellner UF, Grützmann R, Keck T, Werner J, Witzigmann H, Uhl W. Von der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie konsentierte Operationsindikationen beim duktalen Pankreasadenokarzinom. Zentralbl Chir 2020;145:354-64. [DOI: 10.1055/a-1161-9501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Yu X, Gu J, Fu D, Jin C. Dose surgical resection of hepatic metastases bring benefits to pancreatic ductal adenocarcinoma? A systematic review and meta-analysis. International Journal of Surgery 2017;48:149-54. [DOI: 10.1016/j.ijsu.2017.10.066] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
24 Wang L, Yang L, Chen L, Chen Z. Do Patients Diagnosed with Metastatic Pancreatic Cancer Benefit from Primary Tumor Surgery? A Propensity-Adjusted, Population-Based Surveillance, Epidemiology and End Results (SEER) Analysis. Med Sci Monit 2019;25:8230-41. [PMID: 31677259 DOI: 10.12659/MSM.917106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
25 Yamamoto M, Yoshida M, Furuse J, Sano K, Ohtsuka M, Yamashita S, Beppu T, Iwashita Y, Wada K, Nakajima TE, Sakamoto K, Hayano K, Mori Y, Asai K, Matsuyama R, Hirashita T, Hibi T, Sakai N, Tabata T, Kawakami H, Takeda H, Mizukami T, Ozaka M, Ueno M, Naito Y, Okano N, Ueno T, Hijioka S, Shikata S, Ukai T, Strasberg S, Sarr MG, Jagannath P, Hwang TL, Han HS, Yoon YS, Wang HJ, Luo SC, Adam R, Gimenez M, Scatton O, Oh DY, Takada T. Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021. J Hepatobiliary Pancreat Sci 2021;28:1-25. [PMID: 33200538 DOI: 10.1002/jhbp.868] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Jin T, Dai C, Xu F. Surgical and local treatment of hepatic metastasis in pancreatic ductal adenocarcinoma: recent advances and future prospects. Ther Adv Med Oncol 2020;12:1758835920933034. [PMID: 32636941 DOI: 10.1177/1758835920933034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Dolay K, Malya FU, Akbulut S. Management of pancreatic head adenocarcinoma: From where to where? World J Gastrointest Surg 2019; 11(3): 143-154 [PMID: 31057699 DOI: 10.4240/wjgs.v11.i3.143] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Dimopoulos I, Meyer G, Elhabash SI, Sorleto M, Gartung C, Ewald N, Fetzner UK, Otto L, Möhlenbrock F, Uhl W, Gerdes B. [Results of pancreatic surgery from the perspective of patients: a cross-sectional study of the support group "Arbeitskreis der Pankreatektomierten e. V."]. Z Gastroenterol 2021;59:214-24. [PMID: 33506450 DOI: 10.1055/a-1348-2680] [Reference Citation Analysis]
29 Lee RC, Kanhere H, Trochsler M, Broadbridge V, Maddern G, Price TJ. Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases? World J Gastrointest Oncol 2018; 10(8): 211-220 [PMID: 30147847 DOI: 10.4251/wjgo.v10.i8.211] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
30 Gebauer F, Damanakis AI, Bruns C. [Oligometastasis in pancreatic cancer : Current state of knowledge and spectrum of local therapy]. Chirurg 2018;89:510-5. [PMID: 29557488 DOI: 10.1007/s00104-018-0626-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Niesen W, Primavesi F, Gasteiger S, Neoptolemos J, Hackert T, Stättner S. Surgical and local therapeutic concepts of oligometastatic pancreatic cancer in the era of effective chemotherapy. Eur Surg 2019;51:153-64. [DOI: 10.1007/s10353-019-0589-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
32 Sano K, Yamamoto M, Mimura T, Endo I, Nakamori S, Konishi M, Miyazaki M, Wakai T, Nagino M, Kubota K, Unno M, Sata N, Yamamoto J, Yamaue H, Takada T; Japanese Society of Hepato-Biliary-Pancreatic Surgery. Outcomes of 1,639 hepatectomies for non-colorectal non-neuroendocrine liver metastases: a multicenter analysis. J Hepatobiliary Pancreat Sci. 2018;25:465-475. [PMID: 30311741 DOI: 10.1002/jhbp.587] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
33 Shimura M, Mizuma M, Hayashi H, Mori A, Tachibana T, Hata T, Iseki M, Takadate T, Ariake K, Maeda S. A long-term survival case treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver metastasis. Surg Case Rep. 2017;3:132. [PMID: 29285651 DOI: 10.1186/s40792-017-0409-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
34 Bellon E, Gebauer F, Tachezy M, Izbicki JR, Bockhorn M. Pancreatic cancer and liver metastases: state of the art. Updates Surg 2016;68:247-51. [PMID: 27832445 DOI: 10.1007/s13304-016-0407-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
35 Lopez-lopez V, Robles-campos R, López-conesa A, Brusadin R, Carbonel G, Gomez-ruiz A, Ruiz JJ, Parrilla P. Surgical resection of liver metastasis in pancreatic and periampullary carcinoma. Minerva Chir 2019;74. [DOI: 10.23736/s0026-4733.18.07972-5] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
36 Piątek M, Kuśnierz K, Bieńkowski M, Pęksa R, Kowalczyk M, Nawrocki S. Primarily resectable pancreatic adenocarcinoma - to operate or to refer the patient to an oncologist? Crit Rev Oncol Hematol 2019;135:95-102. [PMID: 30819452 DOI: 10.1016/j.critrevonc.2019.01.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
37 Voss N, Izbicki JR, Nentwich MF. Oligometastases in pancreatic cancer (Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis). Ann Gastroenterol Surg 2019;3:373-7. [PMID: 31346576 DOI: 10.1002/ags3.12255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
38 Yoshitomi H, Takano S, Furukawa K, Takayashiki T, Kuboki S, Ohtsuka M. Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. Surg Today 2019;49:894-906. [PMID: 30949842 DOI: 10.1007/s00595-019-01804-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
39 Gebauer F, Damanakis AI, Popp F, Quaas A, Kütting F, Lutz K, Held S, Deuß B, Göser T, Waldschmidt D, Bruns C. Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC). BMC Cancer 2021;21:1239. [PMID: 34794396 DOI: 10.1186/s12885-021-08966-3] [Reference Citation Analysis]
40 Zhou W, Wang D, Lou W. Current Role of Surgery in Pancreatic Cancer With Synchronous Liver Metastasis. Cancer Control 2020;27:1073274820976593. [PMID: 33238715 DOI: 10.1177/1073274820976593] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Damanakis AI, Ostertag L, Waldschmidt D, Kütting F, Quaas A, Plum P, Bruns CJ, Gebauer F, Popp F. Proposal for a definition of "Oligometastatic disease in pancreatic cancer". BMC Cancer 2019;19:1261. [PMID: 31888547 DOI: 10.1186/s12885-019-6448-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
42 Shi HJ, Jin C, Fu DL. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability. World J Gastroenterol 2016; 22(45): 10024-10037 [PMID: 28018110 DOI: 10.3748/wjg.v22.i45.10024] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
43 Höhn P, Braumann C, Nöpel-Dünnebacke S, Munding J, Uhl W, Luu AM. Recurrence of Pancreatic Ductal Adenocarcinoma after Complete Histopathological Remission Caused by FOLFIRINOX. Visc Med 2021;37:149-53. [PMID: 33981756 DOI: 10.1159/000509231] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Su BB, Bai DS, Yu JQ, Zhang C, Jin SJ, Zhou BH, Jiang GQ. Can Patients with Pancreatic Cancer and Liver Metastases Obtain Survival Benefit from Surgery? A Population-Based Study. J Cancer 2021;12:539-52. [PMID: 33391450 DOI: 10.7150/jca.51218] [Reference Citation Analysis]
45 Yang J, Zhang J, Lui W, Huo Y, Fu X, Yang M, Hua R, Wang L, Sun Y. Patients with hepatic oligometastatic pancreatic body/tail ductal adenocarcinoma may benefit from synchronous resection. HPB (Oxford) 2020;22:91-101. [PMID: 31262486 DOI: 10.1016/j.hpb.2019.05.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
46 Sutton TL, Grossberg A, Ey F, O'Reilly EM, Sheppard BC. Multimodality therapy in metastatic pancreas cancer with a BRCA mutation and durable long-term outcome: biology, intervention, or both? Cancer Biol Ther 2021;:1-5. [PMID: 34696697 DOI: 10.1080/15384047.2021.1991739] [Reference Citation Analysis]
47 Ouyang H, Ma W, Zhang T, Liu F, Zhao L, Fang M, Quan M, Pan Z. Systemic chemotherapy in combination with liver-directed therapy improves survival in patients with pancreatic adenocarcinoma and synchronous liver metastases. Pancreatology 2018;18:983-9. [PMID: 30287168 DOI: 10.1016/j.pan.2018.09.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
48 Wei M, Shi S, Hua J, Xu J, Yu X; Chinese Study Group for Pancreatic Cancer (CSPAC). Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1). BMJ Open 2019;9:e033452. [PMID: 31818843 DOI: 10.1136/bmjopen-2019-033452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
49 Renz BW, Boeck S, Roeder F, Trumm C, Heinemann V, Werner J. Oligometastatic Disease in Pancreatic Cancer - How to Proceed? Visc Med 2017;33:36-41. [PMID: 28612015 DOI: 10.1159/000455027] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
50 Schwarz C, Fitschek F, Primavesi F, Stättner S, Margonis GA, Weiss MA, Stavrou GA, Oldhafer KJ, Kornprat P, Wundsam H, Fischer I, Längle F, Függer R, Hauer A, Klug R, Kieler M, Prager G, Schindl M, Stremitzer S, Bodingbauer M, Sahora K, Kaczirek K. Metachronous hepatic resection for liver only pancreatic metastases. Surg Oncol 2020;35:169-73. [PMID: 32889249 DOI: 10.1016/j.suronc.2020.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Tanaka M, Heckler M, Mihaljevic AL, Sun H, Klaiber U, Heger U, Büchler MW, Hackert T. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX. Eur J Surg Oncol 2019;45:1453-9. [PMID: 30981446 DOI: 10.1016/j.ejso.2019.03.039] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
52 Klaiber U, Schnaidt ES, Hinz U, Gaida MM, Heger U, Hank T, Strobel O, Neoptolemos JP, Mihaljevic AL, Büchler MW, Hackert T. Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer. Ann Surg 2021;273:154-62. [PMID: 30921051 DOI: 10.1097/SLA.0000000000003270] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 32.0] [Reference Citation Analysis]
53 Andreou A, Knitter S, Klein F, Malinka T, Schmelzle M, Struecker B, Schmuck RB, Noltsch AR, Lee D, Pelzer U, Denecke T, Pratschke J, Bahra M. The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma. Surg Oncol. 2018;27:688-694. [PMID: 30449494 DOI: 10.1016/j.suronc.2018.09.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
54 Timmer FEF, Geboers B, Nieuwenhuizen S, Schouten EAC, Dijkstra M, de Vries JJJ, van den Tol MP, Meijerink MR, Scheffer HJ. Locoregional Treatment of Metastatic Pancreatic Cancer Utilizing Resection, Ablation and Embolization: A Systematic Review. Cancers (Basel) 2021;13:1608. [PMID: 33807220 DOI: 10.3390/cancers13071608] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Klose J, Ronellenfitsch U, Kleeff J. Management problems in patients with pancreatic cancer from a surgeon's perspective. Semin Oncol 2021:S0093-7754(21)00014-2. [PMID: 34059343 DOI: 10.1053/j.seminoncol.2021.02.008] [Reference Citation Analysis]
56 Li Q, Feng Z, Miao R, Liu X, Liu C, Liu Z. Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution. World J Surg Oncol 2022;20:11. [PMID: 34996486 DOI: 10.1186/s12957-021-02478-x] [Reference Citation Analysis]
57 Ghidini M, Petrillo A, Salati M, Khakoo S, Varricchio A, Tomasello G, Grossi F, Petrelli F. Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality? Cancers (Basel). 2019;11. [PMID: 31374916 DOI: 10.3390/cancers11081095] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
58 Brunner M, Belyaev O, Bösch F, Keck T, Witzigmann H, Grützmann R, Uhl W, Werner J. [Indications for the surgical management of pancreatic neoplasms]. Z Gastroenterol 2021. [PMID: 34820808 DOI: 10.1055/a-1682-7456] [Reference Citation Analysis]